{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:53:07Z","timestamp":1793620387492,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine differentiation (NED) plays a critical role in endocrine therapy resistance and dismal outcomes among prostate cancer (PCa) patients. The emergence of treatment-induced neuroendocrine prostate cancers (t-NEPCs) with the utilization of second-generation androgen receptor (AR) pathway inhibitors (ARPIs) poses a significant challenge, as the molecular underpinnings remain elusive. Here, our investigation unveils a close correlation between heightened levels of opioid receptor membrane protein OPRK1 and treatment-induced NED (t-NED), alongside an adverse prognosis in PCa cohorts. Our findings illuminate that AR represses OPRK1 transcription by binding to its promoter, a regulation amenable to reversal via ARPI administration. Further exploration reveals that OPRK1 stimulation triggers autophagic degradation of REST upon up-regulation and interaction with SLC9A3R1, thereby instigating NED. In essence, OPRK1 experiences negative control by AR and emerges as a pivotal instigator of t-NED. Combining JTC-801 with CQ successfully impedes NEPC progression by impacting the OPRK1\/SLC9A3R1\/autophagy\/REST axis. Our study accentuates OPRK1 as a novel therapeutic target for PCa management and furnishes profound insights into the pathogenesis of t-NEPC.<\/jats:p>","DOI":"10.1038\/s41419-025-08279-4","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:26:59Z","timestamp":1765078019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["OPRK1 drives SLC9A3R1 progression to neuroendocrine prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Linghui","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-7496","authenticated-orcid":false,"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-2760","authenticated-orcid":false,"given":"Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-5392","authenticated-orcid":false,"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-4130","authenticated-orcid":false,"given":"Ruizhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"8279_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8279_CR2","first-page":"767","volume":"365","author":"C Parker","year":"2011","unstructured":"Parker C, Sartor O. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;365:767.","journal-title":"N Engl J Med"},{"key":"8279_CR3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"8279_CR4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/onc.2010.530","volume":"30","author":"ZA Wang","year":"2011","unstructured":"Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene. 2011;30:1261\u201371.","journal-title":"Oncogene"},{"key":"8279_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ncb2697","volume":"15","author":"ZA Wang","year":"2013","unstructured":"Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol. 2013;15:274\u201383.","journal-title":"Nat Cell Biol"},{"key":"8279_CR6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"8279_CR7","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/annonc\/12.suppl_2.S141","volume":"12","author":"H Bonkhoff","year":"2001","unstructured":"Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol. 2001;12:S141\u2013144.","journal-title":"Ann Oncol"},{"key":"8279_CR8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"A Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga A, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"8279_CR9","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20:2846\u201350.","journal-title":"Clin Cancer Res"},{"key":"8279_CR10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492\u2013503.","journal-title":"J Clin Oncol"},{"key":"8279_CR11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"8279_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78\u201383.","journal-title":"Science"},{"key":"8279_CR13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20:890\u2013903.","journal-title":"Clin Cancer Res"},{"key":"8279_CR14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","volume":"7","author":"M Zou","year":"2017","unstructured":"Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017;7:736\u201349.","journal-title":"Cancer Discov"},{"key":"8279_CR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7:54\u201371.","journal-title":"Cancer Discov"},{"key":"8279_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"8279_CR17","doi-asserted-by":"crossref","unstructured":"MYCN transforms prostate epithelium to neuroendocrine prostate cancer. Cancer Discov. 2016;6:OF19.","DOI":"10.1158\/2159-8290.CD-RW2016-066"},{"key":"8279_CR18","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019;129:3924\u201340.","journal-title":"J Clin Invest"},{"key":"8279_CR19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pros.21132","volume":"70","author":"D McKeithen","year":"2010","unstructured":"McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate. 2010;70:982\u201392.","journal-title":"Prostate"},{"key":"8279_CR20","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-15-0137","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin Cancer Res. 2016;22:1510\u20139.","journal-title":"Clin Cancer Res"},{"key":"8279_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","volume":"215","author":"C Chavkin","year":"1982","unstructured":"Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 1982;215:413\u20135.","journal-title":"Science"},{"key":"8279_CR22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0031-6997(25)06958-3","volume":"48","author":"BN Dhawan","year":"1996","unstructured":"Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 1996;48:567\u201392.","journal-title":"Pharmacol Rev"},{"key":"8279_CR23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.psyneuen.2008.01.006","volume":"33","author":"JE Pascoe","year":"2008","unstructured":"Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008;33:478\u201386.","journal-title":"Psychoneuroendocrinology"},{"key":"8279_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/1755-8794-3-43","volume":"3","author":"TL Romanuik","year":"2010","unstructured":"Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genom. 2010;3:43.","journal-title":"BMC Med Genom"},{"key":"8279_CR25","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8279_CR26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"8279_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"8279_CR28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22:369\u201378.","journal-title":"Nat Med"},{"key":"8279_CR29","first-page":"327","volume":"7","author":"S Cheng","year":"2019","unstructured":"Cheng S, Yu X. Bioinformatics analyses of publicly available NEPCa datasets. Am J Clin Exp Urol. 2019;7:327\u201340.","journal-title":"Am J Clin Exp Urol"},{"key":"8279_CR30","volume":"17","author":"HK Tsai","year":"2017","unstructured":"Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017;17:759.","journal-title":"BMC Cancer"},{"key":"8279_CR31","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","volume":"9","author":"C Cai","year":"2014","unstructured":"Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014;9:1618\u201327.","journal-title":"Cell Rep"},{"key":"8279_CR32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","volume":"20","author":"C Cai","year":"2011","unstructured":"Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457\u201371.","journal-title":"Cancer Cell"},{"key":"8279_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","volume":"35","author":"RM Sramkoski","year":"1999","unstructured":"Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. Vitro Cell Dev Biol Anim. 1999;35:403\u20139.","journal-title":"Vitro Cell Dev Biol Anim"},{"key":"8279_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15:271\u201386.","journal-title":"Nat Rev Urol"},{"key":"8279_CR35","doi-asserted-by":"crossref","unstructured":"Sekino Y, Pham QT, Kobatake K, Kitano H, Ikeda K, Goto K et al. HOXB5 overexpression is associated with neuroendocrine differentiation and poor prognosis in prostate cancer. Biomedicines. 2021;9.","DOI":"10.3390\/biomedicines9080893"},{"key":"8279_CR36","doi-asserted-by":"crossref","unstructured":"Hahn O, Heining FM, Janzen J, Becker JCR, Bertlich M, Thelen P et al. Modulating the heat sensitivity of prostate cancer cell lines in vitro: a new impact for focal therapies. Biomedicines. 2020;8.","DOI":"10.3390\/biomedicines8120585"},{"key":"8279_CR37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-023-02776-0","volume":"42","author":"L Yin","year":"2023","unstructured":"Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y, et al. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer. J Exp Clin Cancer Res. 2023;42:204.","journal-title":"J Exp Clin Cancer Res"},{"key":"8279_CR38","volume":"7","author":"YC Lin","year":"2017","unstructured":"Lin YC, Chang YT, Campbell M, Lin TP, Pan CC, Lee HC, et al. MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep. 2017;7:46338.","journal-title":"Sci Rep"},{"key":"8279_CR39","volume":"203","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wu N, Li J, Liang J, Zhou D, Cao Q, et al. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer. Pharmacol Res. 2024;203:107162.","journal-title":"Pharmacol Res"},{"key":"8279_CR40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4047","volume":"227","author":"AV Lapuk","year":"2012","unstructured":"Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012;227:286\u201397.","journal-title":"J Pathol"},{"key":"8279_CR41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/gkt921","volume":"42","author":"C Svensson","year":"2014","unstructured":"Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res. 2014;42:999\u20131015.","journal-title":"Nucleic Acids Res"},{"key":"8279_CR42","doi-asserted-by":"crossref","first-page":"e88556","DOI":"10.1371\/journal.pone.0088556","volume":"9","author":"PC Chang","year":"2014","unstructured":"Chang PC, Wang TY, Chang YT, Chu CY, Lee CL, Hsu HW, et al. Autophagy pathway is required for IL-6-induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS One. 2014;9:e88556.","journal-title":"PLoS One"},{"key":"8279_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bjp.0704478","volume":"135","author":"H Yamada","year":"2002","unstructured":"Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K. Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br J Pharm. 2002;135:323\u201332.","journal-title":"Br J Pharm"},{"key":"8279_CR44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00540-009-0739-2","volume":"23","author":"T Koyama","year":"2009","unstructured":"Koyama T, Fukuda K. Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23:301\u20133.","journal-title":"J Anesth"},{"key":"8279_CR45","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"8279_CR46","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.2147\/DDDT.S69433","volume":"9","author":"A Rodriguez-Vida","year":"2015","unstructured":"Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Dev Ther. 2015;9:3325\u201339.","journal-title":"Drug Des Dev Ther"},{"key":"8279_CR47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bju.14207","volume":"122","author":"R Chen","year":"2018","unstructured":"Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJU Int. 2018;122:560\u201370.","journal-title":"BJU Int"},{"key":"8279_CR48","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1530\/ERC-15-0137","volume":"22","author":"JL Bishop","year":"2015","unstructured":"Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer. 2015;22:R165\u2013182.","journal-title":"Endocr Relat Cancer"},{"key":"8279_CR49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"8279_CR50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2013.05.024","volume":"26","author":"K Mao","year":"2013","unstructured":"Mao K, Wang K, Liu X, Klionsky DJ. The scaffold protein Atg11 recruits fission machinery to drive selective mitochondria degradation by autophagy. Dev Cell. 2013;26:9\u201318.","journal-title":"Dev Cell"},{"key":"8279_CR51","doi-asserted-by":"crossref","first-page":"29672","DOI":"10.1074\/jbc.M111.322404","volume":"287","author":"T Geetha","year":"2012","unstructured":"Geetha T, Zheng C, Vishwaprakash N, Broderick TL, Babu JR. Sequestosome 1\/p62, a scaffolding protein, is a newly identified partner of IRS-1 protein. J Biol Chem. 2012;287:29672\u20138.","journal-title":"J Biol Chem"},{"key":"8279_CR52","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1080\/15548627.2015.1074372","volume":"11","author":"H Liu","year":"2015","unstructured":"Liu H, Ma Y, He HW, Wang JP, Jiang JD, Shao RG. SLC9A3R1 stimulates autophagy via BECN1 stabilization in breast cancer cells. Autophagy. 2015;11:2323\u201334.","journal-title":"Autophagy"},{"key":"8279_CR53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/cdd.2010.191","volume":"18","author":"R Kang","year":"2011","unstructured":"Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18:571\u201380.","journal-title":"Cell Death Differ"},{"key":"8279_CR54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.conb.2005.08.015","volume":"15","author":"N Ballas","year":"2005","unstructured":"Ballas N, Mandel G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr Opin Neurobiol. 2005;15:500\u20136.","journal-title":"Curr Opin Neurobiol"},{"key":"8279_CR55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35:76\u201383.","journal-title":"Nat Genet"},{"key":"8279_CR56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature06780","volume":"452","author":"TF Westbrook","year":"2008","unstructured":"Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008;452:370\u20134.","journal-title":"Nature"},{"key":"8279_CR57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molcel.2008.10.025","volume":"32","author":"P Mulligan","year":"2008","unstructured":"Mulligan P, Westbrook TF, Ottinger M, Pavlova N, Chang B, Macia E, et al. CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell. 2008;32:718\u201326.","journal-title":"Mol Cell"},{"key":"8279_CR58","doi-asserted-by":"crossref","first-page":"26137","DOI":"10.18632\/oncotarget.8433","volume":"7","author":"TP Lin","year":"2016","unstructured":"Lin TP, Chang YT, Lee SY, Campbell M, Wang TC, Shen SH, et al. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget. 2016;7:26137\u201351.","journal-title":"Oncotarget"},{"key":"8279_CR59","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI20039","volume":"112","author":"X Qu","year":"2003","unstructured":"Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Investig. 2003;112:1809\u201320.","journal-title":"J Clin Investig"},{"key":"8279_CR60","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","volume":"41","author":"E Falcon","year":"2016","unstructured":"Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, et al. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology. 2016;41:2344\u201351.","journal-title":"Neuropsychopharmacology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08279-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:23:15Z","timestamp":1769098995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08279-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8279"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08279-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All human-associated tissues used in this research were approved by the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University. Informed consent was signed by all patients before their tissues were acquired.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}}],"article-number":"68"}}